Pure Bioscience - Current report filing (8-K)
January 23 2008 - 3:01PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
January 22, 2008
Date of Report (Date of earliest event reported):
PURE
BIOSCIENCE
(Exact name of registrant as specified in charter)
|
|
|
California
(State or other jurisdiction of incorporation)
|
|
33-0530289
(IRS Employer Identification No.)
|
1725 Gillespie
Way, El Cajon, California 92020
(Address of principal executive offices)
(619) 586
8600
Registrant’s telephone number, including area code:
Check the appropriate box below if
the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the
registrant under any of the following provisions:
[ ] Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange
Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under
the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under
the Exchange Act (17 CFR 240.13e-4(c))
Item 5.02
Departure of Directors of Principal Officers; Election of Directors;
Appointment of Principal Officers
The Directors of PURE Bioscience have
appointed Paul V. Maier to the Board of Directors, effective January 22, 2007. In
connection with his appointment to the Board and in accordance with Company policy, the
Company granted Mr. Maier a fully vested option to purchase 100,000 shares of Company
stock at an exercise price of $5.73 per share, the fair market value of PUREs common
stock on the effective date of Mr. Maiers appointment to the Board.
Mr.
Maier serves on the PURE Bioscience Board as an independent director. Mr. Maier
is not, and has not been for the past three years, employed by the Company or by
any parent or subsidiary of the Company and has not accepted any payments from
the Company or any parent or subsidiary of the Company during the current or any
of the past three fiscal years.
Mr.
Maier served as Vice President, Chief Financial Officer and became Senior Vice
President, Chief Financial Officer of Ligand Pharmaceutical Incorporated from
1992 to 2007. Prior to Ligand Pharmaceutical, Mr. Maier served as Vice
President, Finance at DFS West, a division of DFS Group, L.P., a private
multinational retailer, from October 1990 to October 1992. From February 1990 to
October 1990, Mr. Maier served as Vice President and Treasurer of ICN
Pharmaceuticals, Inc., a pharmaceutical and biotechnology research products
company. Mr. Maier held various positions in finance and administration at SPI
Pharmaceuticals, Inc., a publicly held subsidiary of ICN Pharmaceuticals Group,
from 1984 to 1988, including Vice President, Finance from February 1984 to
February 1987. Mr. Maier received an MBA from Harvard Graduate School of
Business and a B.S. from Pennsylvania State University.
Mr.
Maier is a member of the board of directors of International Stem Cell
Corporation.
No family relationships exist between
Mr. Maier and PURE Bioscience, its directors or officers.
SIGNATURES
Pursuant to the requirements of the
Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed
on its behalf by the undersigned, thereunto duly authorized.
Dated: January 22, 2008
PURE BIOSCIENCE
/s/ MICHAEL L. KRALL
Michael L. Krall, Chief
Executive Officer
PURE Bioscience (PK) (USOTC:PURE)
Historical Stock Chart
From Jun 2024 to Jul 2024
PURE Bioscience (PK) (USOTC:PURE)
Historical Stock Chart
From Jul 2023 to Jul 2024